Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.45 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | DPP4 | P27487 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 6/20 | 0.43 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CTSH | P09668 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CTSC | P53634 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24503296 | 1.00 | SRR (0.48) | SRRPSAT1SLC7A5PTGS1ALPI | |
| SCHEMBL30441 | 1.00 | SRR (0.48) | SRRPSAT1SLC7A5PTGS1ALPI | |
| SCHEMBL30440 | 1.00 | SRR (0.48) | SRRPSAT1SLC7A5PTGS1ALPI | |
| SCHEMBL28466723 | 1.00 | SRR (0.48) | SRRPSAT1SLC7A5PTGS1ALPI | |
| SCHEMBL30439 | 1.00 | SRR (0.48) | SRRPSAT1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL29645 | 0.98 | SRR (0.49) | SRRPSAT1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL29644 | 0.98 | SRR (0.49) | SRRPSAT1SLC7A5PTGS1ALPI | |
| Hydrochloric Acid SCHEMBL29646 | 0.98 | SRR (0.49) | SRRPSAT1SLC7A5PTGS1ALPI | |
| SCHEMBL29077053 | 0.91 | SLC7A5 (0.55) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL30901637 | 0.84 | SRR (0.45) | SRRPSAT1DPP4PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | disclosed |
| US-9802887-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2017-10-31 | — | — | US | disclosed |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | HOOK DAVID (CH) | 2015-10-01 | — | — | US | disclosed |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | HOOK DAVID (CH) | 2015-10-01 | — | — | US | disclosed |
| US-9085529-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-9085529-B2 | Process for the preparation of intermediates useful for the manufacture NEP inhibitors | NOVARTIS AG (CH) | 2015-07-21 | — | — | US | disclosed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| WO-2012025502-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | NOVARTIS AG (CH) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158275-A1 | NEW PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | SRR 566/4885PSAT1 898/4885SLC7A5 255/4885 |
| US-20150274650-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE MANUFACTURE NEP INHIBITORS | MME, DNPEP, REN | SRR 599/4885PSAT1 1001/4885SLC7A5 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.